Drug Discovery

#Biotech #Drug discovery #Financing #Oncology

Laigo Bio raises $17m to advance oncology pipeline  

Biotech company Laigo Bio has completed the second close of its seed financing round with an additional $5.5 million bringing the total investment to $17 million.   Laigo will use the seed financing to accelerate the development of its Surface Removal Targeting Chimeras (SureTACs) oncology programmes towards the clinic. It will… Read More

#Business & Investment #News

The European Medicines Agency in Amsterdam
#Drug discovery #European Medicines Agency #Regulatory

EMA launches tools to accelerate development of medicines

The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need.   After the completion of a two-year pilot, the EMA has integrated these additional tools to support continued scientific… Read More

#News #Regulatory

Obesity concept
#Drug development #Drug discovery

Read the latest issue of DDW

The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications and asks how US tariffs are impacting global pharma. It also looks at how India is… Read More

#Editor's Choice #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Biotherapeutics #Drug discovery #eBook

eBook: A smarter path to ADC quality – fractionate, analyse, decide

A new eBook is now available to download from Bio-Techne entitled ‘Advances in the analysis of next-generation biotherapeutics’. Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics… Read More

#News

#Antibody drug conjugate (ADC) #Biotherapeutics #Drug discovery #eBook

Advances in the analysis of next-generation biotherapeutics

Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics to accelerate development timelines. Learn: icIEF vs IEX for ADC charge profiles Protecting unstable ADCs with on-board mixing… Read More

#eBooks #Resources

BioNTech HQ
#BioNTech #Drug discovery #mRNA

BioNTech co-founders launch new mRNA company

An independent company is to be established and led by BioNTech co-founders Professor Ugur Sahin and Professor Özlem Türeci to “advance next-generation mRNA innovations”.   BioNTech has announced plans to contribute related rights and mRNA technologies to the new company to support the prioritised development of mRNA innovations… Read More

#Business & Investment #News

#Drug discovery #Immunology #Nobel Prize #Osteoporosis #Systems biology

Meet the researcher: Mary Brunkow, Nobel winner 

Mary Brunkow PhD is Senior Program Manager at the Institute for Systems Biology in Seattle in the US. She was one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). She shares her career highlights and some word of wisdom with Diana Turner.  DT: What… Read More

#Exclusive Content #Opinion

#AI / data analytics / healthtech / informatics #Biotech #Drug development #Investment #Market reporting

Treehill Partners: Reflections on JPM and trends for 2026  

DDW Editor Reece Armstrong speaks to Ali Pashazadeh, CEO of capital market company Treehill Partners, about how his experience of this year’s JPM reflects how the industry will move forward in 2026.   The beginning of a new year in drug discovery and development is always marked with the arrival of the JP Morgan Healthcare… Read More

#Business & Investment #Exclusive Content

#Autoimmune disease #Drug discovery #Infectious diseases

Asahi Kasei Pharma strengthens drug discovery pipeline 

Asahi Kasei Pharma has announced a global license agreement with Alchemedicine to strengthen its drug discovery pipeline.  The agreement means Asahi Kasei Pharma can research, develop, manufacture, and commercialise Alchemedicine’s novel lead compounds, which are currently at the preclinical stage.  The compounds were identified using Alchemedicine’s drug discovery platform, HiSAP1 and are expected to… Read More

#Business & Investment #News